Last Update 17 Feb 26

Fair value Increased 14%

CRL: Higher Future P/E Assumptions And Bookings Strength Will Support Share Stability

The analyst price target for Charles River Laboratories International has moved higher by about $27 to reflect updated models that factor in a higher assumed future P/E multiple, modest tweaks to growth and profitability assumptions, and recent Street research pointing to solid book-to-bill trends and a refreshed leadership backdrop.

Analyst Commentary

Recent Street research around Charles River Laboratories International has focused on refreshed price targets, updated models, and the implications of management changes and order trends. Together, these views give you a clearer picture of where analysts see upside potential and where they are more cautious on execution and valuation.

Bullish Takeaways

Bullish analysts have raised price targets across several research updates, reflecting revised models that incorporate new information on the business and its outlook rather than a single one off event.
The reported 4Q book to bill ratio of about 1.1 times is seen by bullish analysts as a supportive data point for forward demand, which they link to a healthier biopharma funding backdrop and potential for steadier revenue visibility.
Some bullish analysts point to the leadership transition, with a new CEO appointed, as an opportunity to refine execution and capital allocation, which they factor into higher valuation assumptions.
Conference related model updates suggest that bullish analysts see enough clarity on the medium term setup to justify higher P/E assumptions, even if they remain focused on execution against those expectations.

Bearish Takeaways

While several targets have moved up, not all analysts have shifted to more positive ratings, which signals ongoing caution around how much upside is already reflected in the share price.
Some research commentary highlights slower healthcare utilization growth trends in broader surveys, which could limit how aggressive growth assumptions can be, even if Charles River is less directly exposed.
The clustering of price target increases around conferences and leadership news also underscores that a portion of the rerating story is sentiment driven, leaving less room for error if execution or end market demand softens.
Overall, even with higher targets, cautious analysts still frame their views around balanced risk and reward, pointing to the need for consistent delivery against updated growth and profitability assumptions to sustain current valuation levels.

What's in the News

Charles River agreed a gene therapy CDMO collaboration with Gazi University Faculty of Medicine to provide plasmid DNA for AAV production and in vitro efficacy studies targeting hyperphosphatemic tumoral calcinosis, using off the shelf, animal component free, royalty free AAV plasmids designed to support early stage programs and help manage costs. (Key Developments)
The company highlighted its broader cell and gene therapy portfolio, which spans discovery and safety assessment services, biologics testing, and manufacturing solutions for plasmid DNA, viral vectors, and cell therapies, as part of its positioning across advanced therapies. (Key Developments)
At the JPMorgan Healthcare Conference, CEO James Foster said Charles River plans to continue expanding its portfolio through M&A, citing around US$4.5b invested in acquisitions since 2012 and referencing recently announced deals and additional transactions under consideration. (Key Developments)
James C. Foster, Chair, President, and CEO, plans to retire at the conclusion of the 2026 Annual Meeting of Shareholders. Current Executive Vice President and Chief Operating Officer Birgit Girshick is appointed as the next CEO and nominated to join the Board at that time, while Mr. Foster will remain a non executive Director. (Key Developments)
Company materials describe a long acquisition led expansion, including more than 50 acquisitions and a shift from a research models focus to a global preclinical contract research organization. Revenue was reported at US$4.0b in 2024 compared with US$307 million in 2000. (Key Developments)

Valuation Changes

Fair Value: updated from $188.93 to $215.73, indicating a higher implied valuation level based on refreshed assumptions.
Discount Rate: adjusted slightly from 8.44% to 8.48%, reflecting a small change in the required return used in the model.
Revenue Growth: revised from 2.72% to 2.52%, representing a modestly lower assumed growth rate.
Net Profit Margin: updated from 11.65% to 11.62%, showing a very small reduction in expected profitability.
Future P/E: increased from 20.40x to 26.80x, reflecting a higher assumed valuation multiple applied to future earnings.

4 views

Key Takeaways

Expansion into advanced therapeutics and investments in automation and digitalization position the company for higher-margin growth and resilience amid regulatory changes.
Strategic cost management, capability diversification, and regulatory resolutions support profitability and position the company for long-term operational stability.
Dependence on animal testing, pricing pressure, demand softness, R&D funding volatility, and execution risks from restructuring threaten revenue growth, margins, and long-term stability.

Catalysts

About Charles River Laboratories International

Charles River Laboratories International, Inc.What are the underlying business or industry changes driving this perspective?

The stabilization and gradual improvement in global biopharma and biotech demand, coupled with an aging global population and increased healthcare spending, are expected to drive sustained recovery and eventual growth in Charles River's core CRO revenues as client R&D pipelines expand and previously delayed projects resume-positively impacting long-term revenue visibility and growth.
Accelerating adoption of advanced therapeutics, such as precision medicine, biologics, and cell & gene therapies, requires specialized preclinical and manufacturing solutions that Charles River is investing in and expanding-supporting a favorable mix, premium pricing, and higher-margin service offerings, which can drive revenue growth and margin expansion.
The company's ongoing diversification and enhancement of its capabilities through investments in new approach methodologies (NAMs), automation, and digitalization, positions it to benefit from industry shifts toward more complex and high-value testing, while also mitigating risks from regulatory and client preferences away from animal testing-improving operational efficiency and supporting future margin stability.
Strategic focus on cost reduction (over $175M in annualized savings expected in 2025), disciplined capital allocation, and improved working capital management not only buttress current profitability but free up cash flow for continued investment in high-growth areas and M&A-strengthening long-term earnings and free cash flow generation.
Positive resolution of regulatory matters (notably, U.S. DOJ clearing Cambodian NHP shipments) alleviates supply constraints and operational risks for non-human primate studies-restoring supply chain predictability and supporting Charles River's ability to meet rising demand in high-value study segments, which underpins both revenue and margin resilience going forward.

Charles River Laboratories International Earnings and Revenue Growth

Charles River Laboratories International Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Charles River Laboratories International's revenue will grow by 2.8% annually over the next 3 years.
Analysts assume that profit margins will increase from -1.7% today to 11.0% in 3 years time.
Analysts expect earnings to reach $483.2 million (and earnings per share of $9.82) by about September 2028, up from $-69.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $540.9 million in earnings, and the most bearish expecting $322 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 19.8x on those 2028 earnings, up from -111.9x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.3x.
Analysts expect the number of shares outstanding to decline by 3.76% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.92%, as per the Simply Wall St company report.

Charles River Laboratories International Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The transition towards non-animal testing methods (NAMs), such as organ-on-chip and in vitro assays, is accelerating, and while Charles River is investing in these areas, the company's core business remains heavily dependent on animal-based preclinical research; long-term client preferences and regulatory shifts away from animal testing could diminish future demand, impacting revenue growth and market share.
Ongoing price competition from international CROs, especially smaller Asian and domestic rivals using aggressive pricing tactics, poses a risk of margin compression, particularly as the company notes spot pricing is only stable and mix-driven improvements are not guaranteed, threatening sustainable improvement in net margins.
The company's recent uptick in cancellations for longer-term post-IND studies and reliance on backlog conversion rather than new bookings (with book-to-bill remaining below 1x) signals that any persistent demand softness or further increase in cancellations could jeopardize the return to organic revenue growth, pressuring both near-term and long-term earnings.
Heavy emphasis on the DSA (Discovery & Safety Assessment) segment exposes Charles River to industry R&D funding volatility; ongoing funding constraints among small biotechs, NIH budget uncertainties, and macro headwinds (e.g., tariffs, US drug pricing regulation) could limit client spend and constrain rebound in revenues, particularly if current stabilization reverses.
Continued restructuring, cost cutting, and integration of acquisitions involve execution risks; higher fixed costs (e.g., new headcount, wage increases) and non-recurring revenue from one-off CDMO client relationships highlight ongoing sensitivity to operational disruptions and variable client demand, threatening the stability of net margins and consistent free cash flow.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $177.067 for Charles River Laboratories International based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $211.0, and the most bearish reporting a price target of just $151.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $4.4 billion, earnings will come to $483.2 million, and it would be trading on a PE ratio of 19.8x, assuming you use a discount rate of 7.9%.
Given the current share price of $157.38, the analyst price target of $177.07 is 11.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Charles River Laboratories International?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

CRL: Improving Demand And Segment Reviews Will Balance Risks In Recovery Period